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ABSTRACT Amphetamine and cocaine are stimulant
drugs that act on central monoaminergic neurons to produce
both acute psychomotor activation and long-lasting behavioral
effects including addiction and psychosis. Here we report that
single doses ofthese drugs induce rapid expression of the nuclear
proto-oncogene c-fos in the forebrain and particularly in the
striatum, an extrapyramidal structure implicated in addiction
and in long-term drug-induced changes in motor function. The
two drugs induce strikingly different patterns of c-fos expression
in the striosome-matrix compartments and limbic subdivisions
of the striatum, and their effects are pharmacologically distinct,
although both are sensitive to dopamine receptor blockade. We
propose that differential activation of immediate-early genes by
psychostimulants may be an early step in drug-specific molec-
ular cascades contributing to acute and long-lasting psycho-
stimulant-induced changes in behavior.
Dramatic changes in behavior occur after exposure to psy-
chomotor stimulant drugs that affect dopaminergic and other
monoaminergic systems in the brain. These changes can
emerge acutely in response to a single exposure or a few
exposures to drugs such as cocaine and amphetamine, and
they can evolve into long-lasting behavioral alterations. The
molecular mechanisms underlying these extended effects are
not understood, but they are thought to involve dopamine
receptors and transporters and to bring about modifications
in the dopamine-containing nigrostriatal and mesolimbic fiber
systems and their neuronal targets in the striatum (1-4).
In the experiments reported here, we explored the possi-
bility, suggested by preliminary experiments (5-9), that psy-
chomotor stimulants induce drug-specific molecular re-
sponses in striatal neurons by activating expression of im-
mediate-early genes. The induction of several immediate-
early genes, whose products influence the transcription of
other genes (10), has been linked to stimulus conditions that
lead to long-term changes in neuronal responsiveness (11-
13). We injected rats with either amphetamine or cocaine and
tested for induction of c-fos, a nuclear proto-oncogene whose
protein product, the DNA-binding protein Fos, is expressed
in a number of neural systems in response to extrinsic signals
(14, 15). We reasoned that expression of Fos could serve as
a sensitive indicator of differential gene activation by psy-
chostimulants in a region of the brain that is directly impli-
cated in the effects of these drugs.
MATERIALS AND METHODS
Drug-naive adult male Sprague-Dawley rats (250-300 g) were
divided into groups receiving (i) no treatment or saline
injections, (ii) injections of either amphetamine or cocaine
alone, or (iii) injections of amphetamine or cocaine in com-
bination with one of the following: the dopamine-depleting
drug reserpine, the dopamine D1 receptor antagonist SCH
23390 (16), the dopamine D2 receptor antagonist YM-09151
(17), the serotonin antagonist metergoline (18), or the sero-
tonin synthesis inhibitor p-chlorophenylalanine (18). All
drugs were administered by intraperitoneal injection; doses
and times are indicated in Table 1.
At the end of the post-treatment survival times, the rats
were deeply anesthetized with Nembutal and perfused trans-
cardially with 0.9% NaCl followed by 4% paraformaldehyde
in 0.1 M sodium phosphate buffer/0.9%o NaCI, pH 7.4. Brains
were post-fixed, blocked, and cut coronally on a Vibratome
at 30-50 ,um, or, rarely, on a sliding microtome at 20-30 gsm
after cryoprotection and freezing. Sections were carried
through standard avidin-biotin immunohistochemical proto-
cols for detection of Fos with one of three polyclonal anti-
sera: Oncogene Science PCO5, Cambridge Research Bio-
chemicals OA-11-823, or Medac OPA 08/1. Control sections
were incubated in the presence of the peptides to which the
antibodies were raised (Cambridge Research Biochemicals,
Cambridge, U.K. and Oncogene Science, Manhasset, NY,
antisera) or without primary antiserum. Sections through the
striatum were stained for Fos in sets permitting serial-section
comparisons between the distribution of neurons expressing
Fos-like immunoreactivity and the distribution of neurons
expressing calbindin D28k (28-kDa calbindin D)-like immuno-
reactivity, a marker (19) for the striosome/matrix organiza-
tion of the striatum (20). For detection of calbindin D28k, we
used polyclonal antisera donated by K. G. Baimbridge (Uni-
versity of British Columbia) (diluted 1:2000) or by P. C.
Emson (Institute of Animal Physiology, Barbaraham, U.K.)
(diluted 1:4000). A few sections were counterstained for
Nissl substance before being coverslipped.
In situ hybridization with an 35S-labeled oligonucleotide
probe for c-fos was performed on 15-gm cryostat sections
from fresh-frozen brains as described by Baldino et al. (21)
with minor modifications. The c-fos probe sequence was
5'-GCA GCG GGA TGA GGC CTC GTA GTC CGC GTT
GAA ACC CGA GAA CAT-3' (Bio-Synthesis, Denton, TX).
Control rats and rats injected with cocaine (1 hr survival)
were used in the in situ hybridization experiments.
RESULTS
Amphetamine and cocaine induced widespread expression of
Fos-like immunoreactivity in neurons of the dorsal or "sen-
sorimotor" striatum (caudoputamen) and ventral or "limbic"
striatum (nucleus accumbens and olfactory tubercle) (Fig. 1).
Dorsomedial and ventrolateral limbic cortex, other limbic
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Table 1. Drug treatments for immunohistochemistry
No. of animals per treatment
with indicated survival times
after last injection*
Treatment Doses i.p., mg/kg '1 hr 1.5-2 hr 3 (or 6) hr
Amphetamine (A) only 5 (or 10) 3 16 (2) 2 (1)
SCH 23390 + A 0.5 + 5 13
YM 90151 + A 0.5 + 5 3
PCPA + A 200 + 5 2
Reserpine + A 10 + 5 15
Chronic reserpine + A 1 + 5 2
Cocaine (C) only 25 (or 50) 4 13 (2) 1 (1)
SCH 23390 + C 0.5 + 25 13
YM 90151 + C 0.5 + 25 2
Metergoline + C 1 (or 5) + 5 1 (1)
Reserpine + C 10 + 25 13
Chronic reserpine + C 1 + 25 2
Doses in mg i.p. per kg of body weight and schedule of drug treatments. The standard series were:
amphetamine with 2-hr survival (A2), cocaine with 2-hr survival (C2), and reserpine 18-hr pretreatment
and amphetamine or cocaine treatment 2 hr before perfusion (R18A2, R18C2). For combined-drug
treatments, times before final amphetamine or cocaine injections were 30 min each for SCH 23390,
YM-90151, and metergoline; 16-18 hr for reserpine (or, for chronic treatment, twice a day for 5 days);
and once a day for 3 days for p-chlorophenylalanine (PCPA). In control experiments, SCH 23390,
YM-90151, PCPA, metergoline, and reserpine were also given individually at the doses indicated for
the combined-drug experiments.
*Numbers in parentheses indicate animals given alternate doses shown in parentheses in lefthand
column.
regions such as the septum, and parts ofnonlimbic cortex and
subcortex were among other sites exhibiting prominent c-fos
induction. The immunostaining was nuclear and in the stri-
atum was principally (if not exclusively) in the medium-sized
neurons that make up 90o or more of all striatal neurons and
are the output neurons of the striatum. Few Fos-positive
striatal neurons were seen in untreated or saline-treated
controls (Fig. 2C). Nuclear immunostaining was absent in
control sections incubated in the presence of Fos peptide
sequences, indicating specificity of the staining for Fos,
Fos-related antigens, or other nuclear antigens having similar
peptide sequences.
Fos-like immunoreactivity was detectable 30-45 min after
intraperitoneal injection of either drug, became pronounced
by 2 hr (standard A2 and C2 series, see Table 1 and Fig. 1),
and had declined by 6 hr. In situ hybridization experiments
carried out on cocaine-treated rats indicated that the psy-
chostimulant activation of Fos was associated with increased
expression of c-fos mRNA and therefore could reflect tran-
scriptional activation of the c-fos gene. There was a strong
B
FIG. 1. Patterns of induction of nuclear Fos-like immunoreactivity in neurons of the caudoputamen (CP), nucleus accumbens (NA), and
olfactory tubercle (Olf T) of rats given intraperitoneal injections of amphetamine (5 mg/kg of body weight) (A) and cocaine (25 mg/kg) (B) 2
hr before perfusion (standard A2 and C2 series of Table 1). Each black dot indicates one Fos-positive nucleus; no distinction is shown between
darkly and weakly stained nuclei (compare with Fig. 2). AC, anterior commissure. (Bar = 0.5 mm.)
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FIG. 2. Charts of zones in the anterior caudoputamen of amphetamine-treated (5 mg/kg of body weight for 2 hr) (A), cocaine-treated (25
mg/kg for 2 hr) (B), and control (untreated) (C) rats. The charts show the distribution of Fos-positive neurons (black dots) in relation to striosomal
borders (solid and dotted forms) drawn from serial sections stained for calbindin D28k. The zones illustrated are from sections at approximately
matched levels. B is from the section shown in Fig. 1B. (Bar = 0.5 mm.)
hybridization signal in the striatum 1 hr after injection of
cocaine (Fig. 3), whereas c-fos mRNA was undetectable in
the striatum in untreated controls.
Strikingly different distributions of Fos-immunoreactive
neurons appeared in the striatum in the amphetamine-treated
and cocaine-treated rats (Fig. 1). In A2 animals, there was a
vividly patchy pattern of Fos expression in the rostral cau-
doputamen (Fig. 1A). By contrast, in the C2 animals, there
was much more homogeneous expression of Fos-like
immunoreactivity (Fig. 1B). To explore this difference, we
compared patterns of Fos-like immunoreactivity in the A2
and C2 animals to the patterns of striatal calbindin D28k-like
immunoreactivity, a marker that demonstrates the patch-
work of striosomes as calbindin-poor zones embedded in a
larger calbindin-positive matrix. The striosomes and matrix
are the major neurotransmitter-specific compartments of the
caudoputamen, and have different input-output connections
and dopaminergic characteristics (20, 22-25).
In the A2 animals, the clusters of neurons with Fos-
immunoreactive nuclei were aligned with calbindin-poor stri-
osomes observed in serially adjacent sections, and these
Fos-positive cell clusters were surrounded by large fields in
which fewer Fos-positive nuclei appeared (Fig. 2A). In the C2
animals, there was generalized induction ofFos-like immuno-
reactivity in both striosomes and matrix, and although Fos-
FIG. 3. In situ hybridization film autoradiogram documenting the
presence of c-fos mRNA in the striatum of a rat treated with cocaine
(25 mg/kg of body weight for 1 hr). CP, caudoputamen; Olf T,
olfactory tubercle; Pir, piriform cortex; C, cingulate gyrus; S,
septum. (Bar = 0.5 mm.)
positive cells were not fully uniform in their distribution, the
Fos expression did not seem selective for either compartment
(Fig. 2B). Striosome-selective expression of Fos was a prom-
inent feature of A2 animals at anterior striatal levels. At
progressively more posterior levels, and especially medially,
Fos expression in matrix cells increased until patchiness at
some levels was no longer apparent or occurred only later-
ally. At more posterior levels in the cocaine brains, the region
of induction tended to become progressively focused within
the medial and dorsal caudoputamen.
The patterns of Fos expression induced by amphetamine
and cocaine also differed in subregions of the ventral stria-
tum. An example is shown in Fig. 1, where numerous
Fos-positive neurons appear in the pyramidal layer of the
olfactory tubercle in the A2 animal but not in the C2 animal.
Cocaine typically elicited less expression of Fos in the core
than in the shell of the nucleus accumbens, a pattern that was
not characteristic of the amphetamine-treated brains.
To determine whether dopamine receptors were necessary
for c-fos activation, we studied the effects ofexposing rats to
D1 and D2 dopamine receptor antagonists before treatment
with amphetamine or cocaine (Table 1). Pretreatment with
the D1 antagonist SCH 23390 almost fully suppressed induc-
tion of c-fos in the striatum in both amphetamine- and
cocaine-treated animals. This strongly suggested that dopa-
mine acting at D1 receptors is involved in the induction but
did not rule out effects on serotonin sites (26). To test for a
serotonin effect, we pretreated rats with the serotonin syn-
thesis inhibitor p-chlorophenylalanine before injection of
amphetamine, and we pretreated other rats with the serotonin
receptor antagonist metergoline before injecting cocaine (Ta-
ble 1). Induction of Fos-like immunoreactivity still occurred
in these brains. Pretreatment with the selective D2 receptor
antagonist YM-09151 greatly diminished Fos activation in the
caudoputamen by amphetamine and cocaine, but YM-09151
by itself induced some Fos activation in the caudoputamen
(compare refs. 27 and 28) so that its influence on subsequent
induction by the psychostimulants could not be fully estab-
lished. YM-09151 alone also led to intense activation in the
ventral striatum, including the nucleus accumbens and the
islands of Calleja. Therefore, we were unable to determine
whether psychostimulant-induced Fos expression in the ven-
tral striatum was dependent on D2 receptor stimulation.
Marked pharmacological differences in the c-fos activation
induced by amphetamine and cocaine were suggested by the
effects of monoamine depletion by reserpine (Table 1). In the
caudoputamen (Fig. 4), acute or chronic pretreatment with
reserpine greatly suppressed subsequent c-fos induction by
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FIG. 4. Photographs showing contrasting effects of reserpine pretreatment on subsequent induction of Fos-like immunoreactivity in the
caudoputamen by amphetamine (A) and cocaine (C). Reserpine (10 mg/kg ofbody weight) was injected 18 hr before perfusion, and amphetamine
(5 mg/kg) and cocaine (25 mg/kg) were injected 2 hr before perfusion (R18A2 and R18C2 series, Table 1). (A and B) Matched zones from adjacent
sections stained, respectively, for Fos-like immunoreactivity (A) and calbindin D28k immunoreactivity (B). (Bar = 0.5 mm.)
cocaine (Fig. 4C). By contrast, amphetamine still evoked
intense expression of Fos in acutely and chronically reser-
pine-pretreated rats (Fig. 4A). Striosomal patterning of Fos
expression was even more pronounced in the reserpine- plus-
amphetamine-treated rats than in many of the rats treated
with amphetamine alone. In R18A2 animals, striosomes
could be recognized throughout the caudoputamen as sites of
especially strong immunostaining despite the presence of
Fos-positive nuclei in the matrix (Fig. 4 A and B). Parallel
effects were found for the ventral striatum in the chronically
reserpine-treated animals: amphetamine still evoked activa-
tion of c-fos expression, but cocaine did not. Acute (18 hr)
treatment with reserpine a-one led to strong expression of
Fos in the ventral striatum, and this pattern was seen also in
the R18A2 and R18C2 animals.
DISCUSSION
The experiments described here establish that brief exposure
to psychomotor stimulant drugs leads to rapid, drug-specific
patterns of gene activation in neurons of the sensory-motor
and limbic striatum. These findings have practical signifi-
cance in suggesting that monitoring immediate-early genes
may be a way to determine directly in in vivo experiments the
central nervous system sites of action of psychostimulants.
The observations also have a direct bearing on studies of the
mechanisms underlying psychostimulant effects.
Our evidence suggests that induction of c-fos in the striatum
by psychomotor stimulants depends on dopamine D1 receptor
stimulation. Therefore, both cAMP/A kinase and calcium or
C kinase signaling may underlie the induction, forD1 receptors
are positively coupled to adenylate cyclase (29) and to inositol
phospholipid (30) signaling pathways. It has been shown in in
vitro experiments that the transcription ofc-fos can be induced
through interaction of nuclear proteins with cAMP-responsive
regulatory elements (CREs) present in the gene (31), and some
C kinase effects have been reported as well (32). Our findings
also implicate D2 dopamine receptors in the psychomotor
stimulant induction of c-fos, at least in the caudoputamen. D2
receptors also act on cAMP/A kinase and calcium or C kinase
signaling pathways through negative direct [inhibitory guanine
nucleotide-binding (G,) protein] or indirect coupling (33, 34).
Di-selective but not D2-selective dopamine agonists have
been shown to activate c-fos in the dopamine-depleted stria-
tum of rats treated unilaterally with the neurotoxin 6-hydrox-
ydopamine (6).
The molecular sequels to this c-fos induction by psycho-
stimulants are unknown, but they may involve further protein
synthesis. Fos is known to act in heterodimeric association
with other members of the Jun/AP-1 family of nuclear
proteins to control the transcriptional activity of a number of
other genes (35). Interestingly, both Fos (32, 36) and dopa-
mine receptors (25, 37) have been directly implicated in
regulation of neuropeptide genes including those of opioid
peptides that are abundant in many medium-sized neurons of
the striatum. Moreover, the opiate antagonist naloxone (38,
39) and the mixed opiate agonist-antagonist buprenorphine
(40) block some of the addictive/reinforcing effects of co-
caine, and morphine itself induces c-fos in the striatum (41).
There thus may be a link between psychostimulant induction
of c-fos and subsequent changes in neuropeptide expression
in the striatum.
Our findings suggest that the mechanisms of c-fos induc-
tion triggered by cocaine and by amphetamine, though shar-
ing some characteristics, are nevertheless distinct both phar-
macologically and anatomically. First, the effects of cocaine
on c-fos in the striatum are mediated by reserpine-sensitive
pools of monoamine, whereas striatal c-fos induction by
amphetamine is not blocked by reserpine. These findings
raise the interesting possibility that the long-standing phar-
macological classification of reserpine-sensitive and reser-
pine-insensitive pools of releasable catecholamine (42, 43)
and their mobilization by psychostimulants (44, 45) may be
related to the patterns of proto-oncogene induction described
here. Second, the induction of c-fos by amphetamine was
especially prominent in the striosomal system, whereas the
induction of c-fos by cocaine occurred widely in both striatal
compartments. This result suggests that the striosome and
matrix compartments of the caudoputamen, with their dif-
ferent limbic and sensory-motor affiliations with cortex and
subcortex (24, 46), contribute differently to the functional
effects of cocaine and amphetamine.
Striosomes and matrix are known to have contrasting
dopaminergic properties asjudged by their profiles of in vitro
binding for dopamine D1- and D2-selective ligands (47-49)
and monoamine uptake-site ligands (50, 51) and by the
characteristics of their mesostriatal innervations (52-56).
Together with the differential effects of amphetamine and
cocaine on monoamine release (greater for amphetamine) and
reuptake (greater for cocaine) (42, 57), these characteristics
could be critical to the pharmacological as well as the spatial
distinctiveness of the psychostimulant effects. Understand-
ing these differences could have particular functional impor-
C
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tance, given that amphetamine and cocaine, although show-
ing cross-tolerance, have appreciably different effects on
behavior (58).
The enduring behavioral changes that follow exposure to
amphetamine and cocaine are at once the most puzzling and
potentially the most detrimental effects ofthese psychomotor
stimulants. Our findings raise the possibility that dopamine-
regulated plasticity in gene transcription in the striatum may
underlie some ofthese long-term influences on neural activity
and behavior.
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